A second big grant to WPD Pharmaceuticals
Jan 31, 2019We work closely in collaboration with WPD Pharmaceuticals, a new Polish pharmaceutical industry start-up which launched in late 2017. The company is a partner in our FNP FIRST TEAM and TEAM-TECH CORE FACILITY projects, while we host some of the team in our laboratory for execution of their WPD101 project.
On the 31st of January 2019 National Center for Research and Development announed a list of projects recommended for co-financing by the European Union, under the Smart Growth Operational Program 2014-2020, Sectoral Programme InnoNeuroPharm (Priority Axis I: Support R&D carried out by enterprises, Measure 1.2 Sectorial programms R&D).
WPD Pharmaceuticals will receive founding in the amount 22 033 066 PLN for the new drug development as a part of the project “New approach to glioblastoma treatment addressing the critical unmet medical need”. This second big project, WPD104, will join WPD101 in an exciting portfolio of anticancer therapies under development by WPD Pharmaceuticals.
Enthusiastic congratulations to our colleagues at WPD Pharmaceuticals!
